Fijians nationwide are grappling with ongoing medicine shortages, causing delays in accessing essential treatments. The Pharmaceutical and Biomedical Services (FPBS), responsible for supplying over 200 health facilities, has identified both internal and external factors contributing to these supply disruptions. This network includes three divisional hospitals, twelve specialist hospitals, twenty-one sub-divisional hospitals, ninety-four health centers, and forty-seven nursing stations.
Jeremaia Mataika, the FPBS Director, has pointed out that some suppliers are not meeting quality standards as per their contractual obligations, leading to the return of substandard medicine batches and worsening the situation. He noted that shortages are particularly critical for non-communicable diseases (NCDs), especially during spikes in demand. Additionally, bureaucratic delays in procurement approvals from the Solicitor-General’s Office are compounding the issue.
Minister for Health and Medical Services, Dr. Ratu Atonio Lalabalavu, confirmed that contracts with certain suppliers have been terminated due to non-compliance with agreed standards. He emphasized that alternative solutions are being sought to fill the gaps left by these terminations.
The impact of these medicine shortages is concerning, particularly for patients managing chronic conditions, as the lack of timely access to effective drugs may disrupt their care and elevate health risks. Public health experts are advocating for a comprehensive revision of Fiji’s medicine procurement process to enhance transparency, accountability, and efficiency.
Critics point out that the current frameworks, bound by the Financial Management Act 2004 and Procurement Regulation 2010, are inflexible and inadequate in addressing urgent health needs. A healthcare advocate expressed the urgency by stating, “This is not just about processes or regulations. It’s about ensuring every Fijian can access safe, effective medicines when they need them.”
While the Ministry of Health and Medical Services acknowledges the need for reform, they face the challenge of implementing systemic changes to protect the country’s most vulnerable populations.
In summary, Fiji is facing significant challenges in its healthcare supply chain due to procedural bottlenecks and supplier issues, necessitating urgent reform to ensure patients receive the treatment they require. With ongoing discussions for improvement, there is hope that solutions will emerge to restore access to vital medicines for all.
Leave a comment